Recent Updates
Recently added Catalysts
ANRO Negative Sentiment Score: 25/100

Alto Neuroscience, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 19, 2025 to Discuss Your Rights – ANRO

Key Takeaway: Alto Neuroscience, Inc. (NYSE: ANRO) is facing a securities lawsuit concerning alleged misleading statements made during its initial public offering in February 2024. Shareholders who purchased shares between February 2, 2024, and October 22, 2024, are encouraged to register for potential class action participation. The allegations highlight concerns regarding the effectiveness of the company’s product, ALTO-100, for treating major depressive disorder and suggest that prior statements about the company's prospects were misleading. A deadline of September 19, 2025, has been set for shareholders to register their interest in joining the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • The company is facing a lawsuit for securities law violations.
  • Allegations include materially false and misleading statements regarding the product pipeline.
  • Concerns raised about the effectiveness of the treatment for major depressive disorder.
  • The company's business and financial prospects have been overstated.

Full Press Release Details

NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO).
Shareholders who purchased shares of ANRO during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: This lawsuit is on behalf of a class consisting of all persons and entities that purchased or otherwise acquired: (a) Alto common stock pursuant and/or traceable to the Offering Documents issued in connection with the Company’s initial public offering conducted on or about February 2, 2024; and/or (b) Alto securities between February 2, 2024 and October 22, 2024, both dates inclusive.
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) The Company’s product pipeline, ALTO-100, was less effective in treating major depressive disorder than defendants had led investors to believe; (ii) accordingly, ALTO-100’s clinical, regulatory, and commercial prospects were overstated; (iii) as a result, Alto’s business and/or financial prospects were overstated; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
DEADLINE: September 19, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/alto-neuroscience-inc-loss-submission-form/?id=166110&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of ANRO during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 19, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

Who can join the Alto Neuroscience class action?

All persons and entities who purchased ANRO shares between February 2, 2024, and October 22, 2024, can join.

What are the allegations against Alto Neuroscience?

The allegations include misleading statements regarding ALTO-100's effectiveness and overstated business prospects.

When is the lead plaintiff appointment deadline?

The deadline to seek lead plaintiff status is September 19, 2025.

What happens after registering with Gross Law Firm?

Registered shareholders will receive updates through portfolio monitoring software about the case.

Is there a fee to participate in the class action?

There is no cost or obligation for shareholders to participate in the class action.

Last updated: Sep 10, 2025